Boehringer Ingelheim announced the grand opening of its newly expanded research and development facility in Athens, Georgia. As the largest animal health company in Georgia, this Boehringer ...

AllianceQUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery 24.10.2024 / 09:30 CET/CESTThe issuer is solely responsible for the content of this ...

Global Pleural Diseases Therapeutics MarketThe global market for pleural diseases therapeutics is projected to experience ...

One of the primary factors fueling the growth of the DOACs market is the rapid uptake and expected utilization within the ...

Madrigal faces financial challenges and competition for Rezdiffra. Read more to understand why MDGL stock is downgraded from ...

Pediatric Orphan Drug Market is Segmented by Type (Oncology, Pulmonary, Neurology, Hematology, Endocrinology, Cardio-vascular, Metabolic Disorders), by Application (0-1 Years, 1-3 Years, 3-6 Years, ...

FRANKFURT: The CEO of pharmaceuticals giant Roche, opens new tab said authorities should block the takeover of contract drug ...

Shares of Catalent CTLT lost 0.9% on Oct. 23 with the rise in uncertainty related to its acquisition by Novo Holding ...

As the EU patent expires on its flagship respiratory diseases product, Spiriva, Boehringer Ingelheim is looking to newer diabetes and respiratory drugs under the leadership of a new CEO.

Advances in Therapy to Address Proteinuria in Patients with Immunoglobulin A Nephropathy. As the majority of patients with ...